Vireo Growth (VREOF) Total Current Liabilities (2020 - 2026)
Vireo Growth (VREOF) posted Total Current Liabilities of $215.8 million for Q1 2026, up 12.57% sequentially from $191.7 million in Q4 2025, and up 56.77% YoY from $137.7 million in Q1 2025.
Vireo Growth (VREOF) Total Current Liabilities (2020 - 2026) Analysis & Trends
Vireo Growth has reported Total Current Liabilities for 7 years, with the latest figure at $215.8 million in Q1 2026.
- Quarterly Total Current Liabilities rose 56.77% year-over-year to $215.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215.8 million (up 56.77% YoY) and the FY2025 annual result came in at $191.7 million, up 41.51% from the prior year.
- Total Current Liabilities rose to $215.8 million in Q1 2026 per VREOF's latest filing, from $191.7 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $243.5 million in Q2 2025 and troughed at $18.5 million in Q2 2022.
- A 5-year average of $138.3 million and a median of $157.0 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 747.46% in 2023, then decreased 25.28% in 2025.
- Over 5 years, Total Current Liabilities stood at $29.7 million in 2022, then jumped by 504.09% to $179.5 million in 2023, then declined by 24.52% to $135.5 million in 2024, then soared by 41.51% to $191.7 million in 2025, then increased by 12.57% to $215.8 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $215.8 million, $191.7 million, and $234.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 1.79 Bn |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | 390.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215.80 Mn |
| Dec 31, 2025 | 191.70 Mn |
| Sep 30, 2025 | 234.91 Mn |
| Jun 30, 2025 | 243.52 Mn |
| Mar 31, 2025 | 137.66 Mn |
| Dec 31, 2024 | 135.47 Mn |
| Sep 30, 2024 | 128.77 Mn |
| Jun 30, 2024 | 186.77 Mn |
| Mar 31, 2024 | 184.24 Mn |
| Dec 31, 2023 | 179.47 Mn |
| Sep 30, 2023 | 165.42 Mn |
| Jun 30, 2023 | 157.00 Mn |
| Mar 31, 2023 | 95.17 Mn |
| Dec 31, 2022 | 29.71 Mn |
| Sep 30, 2022 | 26.35 Mn |
| Jun 30, 2022 | 18.53 Mn |
| Mar 31, 2022 | 20.52 Mn |
| Dec 31, 2021 | 16.41 Mn |
| Sep 30, 2021 | 15.23 Mn |
| Jun 30, 2021 | 16.11 Mn |